In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx (NASDAQ: RARE). The company’s shares closed yesterday at $83.90, close to its 52-week high of $87.33.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 3.5% and a 42.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $90.22 average price target, representing a 7.5% upside. In a report issued on August 17, SunTrust Robinson also reiterated a Buy rating on the stock with a $83 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $87.33 and a one-year low of $41.67. Currently, Ultragenyx has an average volume of 502.1K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
